Jagsonpal Pharmaceuticals Ltd Q2 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/vozpz4yl5kddhhpwsgvq5iwl.pdf

Key Takeaways


The GST Transition & Quarter Mechanics

Manish Gupta: "I believe India is not one market but multiple markets. And so there is a place for trade generics. The customer base for trade generics is different so also for Jan Aushadhi."

Portfolio Dynamics & the Dydrogesterone Overhang

Manish Gupta: "We do not intend to launch like a GLP-1 on the date of patent expiry because we know 80-guys will be there on day-one. So, our new product launches are always going to be in more difficult categories where we have to do concept selling, therefore the buildup will be slower but more sustainable."

Yash Pharma Integration

Manish Gupta: "Today it gives me greater confidence to go and acquire something going forward and taking a bigger step compared to what I would have done earlier, because it was not about me, it is about the JPL capability."

MR Productivity & the Operating Leverage Thesis

Manish Gupta: "Our profitability is where it is in spite of low MR productivity. So, therefore, as the sales grow faster than the marketplace, the accretive value creation or profitability impact will be much higher for us vis-a-vis growth, which would have come from enhanced MR numbers."

M&A Appetite & Capital Allocation

Manish Gupta: "I will definitely expect Jagsonpal to be more aggressive, but certainly, it is not feasible for us to be as aggressive as Torrent in terms of the value and all whose scale is so different now, that a small mistake will not cost them the Company. In our case, we are not big enough to take a big mistake."

Guidance & Commitments

CommitmentSpecificsTimeline
FY26 revenue growthTargeting ~10% overall for the year; low double-digit for the remainderFY26
H2 performanceStronger second half now that GST transition is behindH2 FY26
Medium-term growth~10% growth as an organisation, with acceleration thereafterMedium-term
Aspirational growth planManagement to share more detailed strategic plans"A couple of weeks" from call date
New product launchesLaunches planned for the rest of the year; details only at launchFY26
M&A postureMore aggressive than the past; open to chronic and beyond current sub-chronic focusOngoing

Key Metrics

MetricQ2 FY26
Revenue₹74.5 cr, flat YoY due to GST transition impact
H1 FY26 revenue₹150 cr, +10% YoY
EBITDA₹18.1 cr, margin 24.3%
H1 FY26 EBITDA₹33.8 cr, +9% YoY, margin 22.5%
PAT₹12.6 cr, +10% YoY, margin close to 17%, up 150 bps
H1 FY26 PAT growth~39% YoY
Cash balance₹160.4 cr, maintained vs June despite ₹16.7 cr dividend payout
Dividend paid₹16.7 cr, 125% or ₹2.5 per share
FY26 revenue growth target~10% for the full year, low double-digit for H2
Indian pharma market growth~7.5% in Q2 FY26, driven by price and new launches
Jagsonpal's therapy-area market growth2.5% to 3% during the quarter
Top 5 brands growth3% to 4% for some, flattish for others
Brands in ₹50 cr club1 brand, Indocap group, in early 50s
MR count~1,000 across four divisions
MR attrition rate~30%